PTO Explains Proposed Guidelines

When inventors apply for a patent, they must set forth the utility of their invention and describe it. Which utilities and description meet the grade, and which don't? The U.S. Patent and Trademark Office (PTO) recently proposed new guidelines for its examiners. These guidelines were discussed in an article titled "Biotech Faces Evolving Patent System" in the last issue of The Scientist.1 PTO had not at that time published specific examples of how the guidelines would be interpreted. The office

Written byDouglas Steinberg
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

When inventors apply for a patent, they must set forth the utility of their invention and describe it. Which utilities and description meet the grade, and which don't? The U.S. Patent and Trademark Office (PTO) recently proposed new guidelines for its examiners. These guidelines were discussed in an article titled "Biotech Faces Evolving Patent System" in the last issue of The Scientist.1 PTO had not at that time published specific examples of how the guidelines would be interpreted. The office did so on March 1, issuing training materials replete with examples, most of which pertain to biotech (www.uspto.gov).

In focusing on the "genus" and "species" of a claimed invention, the written-description examples are legally and scientifically complex. They're best discussed with a patent agent or lawyer. The utility examples (www.uspto.gov/web/offices/pac/utility/utilityguide.pdf.) should also be explained by a professional but are generally more colorful and approachable. Here are some of their do's ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies